Primary Breast Cancers are Reduced by Raloxifene

University of Pennsylvania Cancer Center
Ultima Vez Modificado:: 19 de mayo de 1998

In a second analysis of the study presented yesterday, researchers found that the risk of developing breast cancer was reduced by 58% in women taking Raloxifene, compared to women receiving a placebo. This dramatic reduction was observed in postmenopausal women being treated for osteoporosis who had no history of breast cancer. The researchers conclude that there is substantial evidence for a profound reduction in the risk of developing breast cancer for patients taking Raloxifene.

Raloxifene has target-site specific estrogen agonist effects on bone and lipid an antagonist effects on breast and uterine tissue, via modulation an high affinity binding to the estrogen receptor on tumor cells.

[ Original Abstract ]


A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
R
S
T
U
V
X
Y
Z
#
 
A
B
C
E
F
G
H
K
L
M
N
O
P
R
S
T
U
V
 
 
Manténgase informado con las últimas informaciones de OncoLink!   Subscribe to OncoLink eNews
View our newsletter archives